SB 221

Drug Profile

SB 221

Alternative Names: SB-221; Tensostat

Latest Information Update: 16 Jun 2015

Price : $50

At a glance

  • Originator SunTen Phytotech
  • Developer Lumosa Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cardiovascular disorders

Highest Development Phases

  • Phase II Cardiovascular disorders; Dyslipidaemias; Essential hypertension

Most Recent Events

  • 16 Jun 2015 SB 221 is still in phase II trials for Cardiovascular disorders and Essential hypertension
  • 16 Jun 2015 SB 221 is still available for licensing (http://www.lumosa.com.tw)
  • 14 May 2008 SB 221 is available for licensing (http://www.stpt.com.tw)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top